Skip to content
Open access

Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK

Aug 2026 · Pharmaceuticals · Vol 19 · 0 citations · 62 references
Medicine

TL;DR

This integrated ML-to-simulation workflow prioritizes structurally novel candidate hits with predicted ALK inhibitory activity and provides an effective strategy for scaffold discovery and hit prioritization.

Abstract

Background: Anaplastic Lymphoma Kinase (ALK) is an oncogenic receptor tyrosine kinase implicated in several cancers. Despite the clinical success of ALK inhibitors, acquired resistance continues to drive the search for novel chemotypes. We developed a multiclass machine learning framework to classify ALK inhibitory activity using a curated ChEMBL dataset. Methods: Models were built using 2D molecular descriptors together with MACCS and ECFP4 fingerprints. Three widely used algorithms, Support Vector Machine (SVM), Random Forest (RF), and XGBoost, were applied for model development. Results: RF and XGBoost models demonstrated the best performance, achieving accuracies of ~0.75–0.79 with consistently high ROC–AUC values, particularly for fingerprint-based features. Bemis–Murcko scaffold analysis identified enriched chemotypes and underexplored scaffolds for further prioritization. The validated models were subsequently used to screen the Maybridge library, and compounds predicted to possess potential ALK inhibitory activity were prioritized for further computational evaluation. Applicability-domain filtering confirmed that the selected compounds occupied the predicted ALK inhibitor chemical space across multiple activity classes. The shortlisted compounds were subsequently evaluated by molecular docking to characterize their binding modes and interactions. Three candidate hits (SCR00078, SCR00073, and AW01085) were selected for further evaluation using 500 ns molecular dynamics simulations alongside the reference inhibitor Brigatinib. Simulation analyses revealed stable protein–ligand complexes and reduced conformational fluctuations relative to apo ALK, while MM/PBSA calculations identified SCR00078 and AW01085 as the most favorable binders. Conclusions: This integrated ML-to-simulation workflow prioritizes structurally novel candidate hits with predicted ALK inhibitory activity and provides an effective strategy for scaffold discovery and hit prioritization.

Read PDF

Similar papers

#protein folding Aug 2026

P1.062. Discovery of Novel Dual-Target Inhibitors for EGFR and PIK3CA From Natural Products via Machine Learning and Molecular Simulation

The natural product compounds CNP0456830 and CNP0467494 exhibited the lowest binding free energies for both EGFR and PIK3CA, identifying them as the most promising dual-target inhibitors.

Si-miao Lu, Yi Zhu, Yong-Tao Han et al. · 0 citations
Open access Jul 2026

Computational design and AI driven discovery of anaplastic lymphoma kinase inhibitors for non small cell lung cancer treatment

Artificial intelligence and computational techniques employed to screen a library of ALK tyrosine kinase inhibitors, retrieved from ChEMBL database, suggest that briga_15 and crizo_35 are promising leads warranting further optimization, synthesis, and biological evaluation.

O. Oyeneyin, N. Ipinloju, N. Gumede · 0 citations
Open access Jul 2026

Machine learning–driven identification of PIM2 kinase inhibitors through QSAR modeling and molecular dynamics simulations

An integrated machine learning–guided computational pipeline was developed to identify potential PIM2 inhibitors by combining quantitative structure–activity relationship (QSAR) modeling, virtual screening, molecular docking, molecular dynamics simulations, and pharmacokinetic prediction, highlighting the potential of...

A. Fahira, M. Shahab, Zaheer Ud Din et al. · 0 citations
Open access Aug 2026

From Descriptor Learning to Binding Stability: An Explainable Machine Learning Pipeline for EGFR Double-Mutant Inhibitor Discovery

An integrated computational workflow combining explainable machine learning, virtual screening, molecular dynamics simulations, and binding free-energy calculations to identify novel inhibitors of this drug-resistant EGFR variant may support the development of new therapeutic strategies for overcoming resistance in EGF...

Jurica Novak · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.